- Home
- PD vs AKRO Comparison
PD vs AKRO Comparison
Compare PD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PD
- AKRO
- Stock Information
- Founded
- PD 2009
- AKRO 2017
- Country
- PD United States
- AKRO United States
- Employees
- PD N/A
- AKRO N/A
- Industry
- PD Computer Software: Prepackaged Software
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PD Technology
- AKRO Health Care
- Exchange
- PD Nasdaq
- AKRO Nasdaq
- Market Cap
- PD 1.4B
- AKRO 3.9B
- IPO Year
- PD 2019
- AKRO 2019
- Fundamental
- Price
- PD $15.99
- AKRO $51.77
- Analyst Decision
- PD Buy
- AKRO Strong Buy
- Analyst Count
- PD 12
- AKRO 6
- Target Price
- PD $19.50
- AKRO $82.50
- AVG Volume (30 Days)
- PD 1.6M
- AKRO 1.7M
- Earning Date
- PD 09-02-2025
- AKRO 08-08-2025
- Dividend Yield
- PD N/A
- AKRO N/A
- EPS Growth
- PD N/A
- AKRO N/A
- EPS
- PD N/A
- AKRO N/A
- Revenue
- PD $476,132,000.00
- AKRO N/A
- Revenue This Year
- PD $9.60
- AKRO N/A
- Revenue Next Year
- PD $7.56
- AKRO N/A
- P/E Ratio
- PD N/A
- AKRO N/A
- Revenue Growth
- PD 8.55
- AKRO N/A
- 52 Week Low
- PD $13.70
- AKRO $21.02
- 52 Week High
- PD $22.51
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PD 59.65
- AKRO 49.14
- Support Level
- PD $15.09
- AKRO $51.08
- Resistance Level
- PD $16.49
- AKRO $57.35
- Average True Range (ATR)
- PD 0.46
- AKRO 2.21
- MACD
- PD 0.20
- AKRO -0.81
- Stochastic Oscillator
- PD 94.64
- AKRO 11.08
About PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.